Autonomix Medical, Inc. (AMIX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Autonomix Medical, Inc. on October 22, 2024. The report details a corporate action approved by stockholders at the annual meeting held on October 17, 2024, and executed by the Board of Directors to effect a reverse stock split.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed relates to capital structure adjustments:
- Pre-Split Outstanding Shares: Approximately 23.0 million shares.
- Post-Split Outstanding Shares: Approximately 1.15 million shares.
- Authorized Shares: Remains at 500 million shares.
- Par Value: Remains at $0.001 per share.
Material Changes
The material change reported is the implementation of a 1-for-20 reverse stock split. Key details include:
- Effective Time: 11:59 p.m. Eastern Time on October 24, 2024.
- Trading Resumption: October 25, 2024, on The Nasdaq Capital Market under the ticker symbol "AMIX" with a new CUSIP number (05330T205).
- Adjustments: Proportionate adjustments will be made to the exercise prices and share counts of outstanding stock options, restricted stock units, warrants, and convertible notes.
- Fractional Shares: No fractional shares will be issued; entitlements will be rounded up to the nearest whole number.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the summary of the Amendment is qualified by reference to the full text of the Amendment (Exhibit 3.1). The action was taken to maintain compliance with listing standards or improve marketability, though the specific rationale is not detailed in this excerpt.
Investor Verification Checklist
- Verify the new CUSIP number (05330T205) for trading purposes starting October 25, 2024.
- Confirm the adjusted exercise prices and share counts for any held stock options, warrants, or convertible notes.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for complete legal terms.
- Monitor the post-split trading volume and price to assess market reception.